  Genetic alterations initiate tumors and enable the evolution of drug
resistance. The pro-cancer view of mutations is however incomplete, and several
studies show that mutational load can reduce tumor fitness. Given its negative
effect, genetic load should make tumors more sensitive to anticancer drugs.
Here, we test this hypothesis across all major types of cancer from the Cancer
Cell Line Encyclopedia, which provides genetic and expression data of 496 cell
lines together with their response to 24 common anticancer drugs. We found that
the efficacy of 9 out of 24 drugs showed significant association with genetic
load in a pan-cancer analysis. The associations for some tissue-drug
combinations were remarkably strong, with genetic load explaining up to 83% of
the variance in the drug response. Overall, the role of genetic load depended
on both the drug and the tissue type with 10 tissues being particularly
vulnerable to genetic load. We also identified changes in gene expression
associated with increased genetic load, which included cell-cycle checkpoints,
DNA damage and apoptosis. Our results show that genetic load is an important
component of tumor fitness and can predict drug sensitivity. Beyond being a
biomarker, genetic load might be a new, unexplored vulnerability of cancer.
